Drug profile · INN
esketamine hydrochloride
SPRAVATO
esketamine hydrochloride (SPRAVATO) is a glutamate [nmda] receptor negative allosteric modulator. Route of administration: nasal. Current US regulatory status: approved.
Drug details — esketamine hydrochloride
- US status
- approved
- Class
- —
- Route
- NASAL
- Patents
- 1
- Programs
- 17
- Data quality
- 0.84
Quick answer
esketamine hydrochloride (SPRAVATO) is a glutamate [nmda] receptor negative allosteric modulator. Route of administration: nasal. Current US regulatory status: approved.
Key facts
Mechanism of action
Glutamate [NMDA] receptor negative allosteric modulator
Primary target: Glutamate [NMDA] receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is esketamine hydrochloride?
esketamine hydrochloride (SPRAVATO) is a glutamate [nmda] receptor negative allosteric modulator. Route of administration: nasal. Current US regulatory status: approved.
What is the brand name for esketamine hydrochloride?
SPRAVATO is a marketed brand name for esketamine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of esketamine hydrochloride?
esketamine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.